Windlas Biotech Limited (BOM:543329)

Market Cap	20.50B -4.4%
Revenue (ttm)	9.42B +18.5%
Net Income	664.44M +1.9%
EPS	31.13 +1.2%
Shares Out	n/a
PE Ratio	30.86
Forward PE	n/a
Dividend	6.30 (0.64%)
Ex-Dividend Date	Jul 16, 2026

Volume	6,450
Open	998.40
Previous Close	985.30
Day's Range	954.80 - 1,008.60
52-Week Range	699.35 - 1,043.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 1,385
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543329

Financial Performance

In fiscal year 2026, Windlas Biotech's revenue was 9.04 billion, an increase of 18.98% compared to the previous year's 7.60 billion. Earnings were 664.56 million, an increase of 8.95%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error